Use of nonmyeloablative preparative regimens for allogeneic blood stem cell transplantation: Induction of graft-vs.-Malignancy as treatment for malignant diseases

Journal of Clinical Apheresis

Volumn 14, Issue 1, 1999, Pages 45-49

  Champlin, Richard ^a   Khouri, Issa ^a   Giralt, Sergio ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOMA; MULTIPLE MYELOMA; SOLID TUMOR; T LYMPHOCYTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; GRAFT VS HOST REACTION; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; NEOPLASMS; PILOT PROJECTS; RECURRENCE; REMISSION INDUCTION; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032910269     PISSN: 07332459     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1101(1999)14:1<45::AID-JCA9>3.0.CO;2-R     Document Type: Conference Paper

References (65)

1. Thomas ED. Bone marrow transplantation for malignant disease. J Clin Oncol 1983;1:517.
2. Thomas ED. The role of bone marrow transplantation for eradication of malignant disease. Cancer 1969;10:1963.
3. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, The Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981;304:1529.
4. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb H-J, Rimm AA, Ringdén O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555.
5. Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL, Witherspoon RP, Appelbaum FR, Banaji M, Hansen J, Martin P, Sanders JE, Singer J, Thomas ED. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989;320:828.
6. Gale RP, Champlin RE. How does bone marrow transplantation cure leukemia? Lancet 1984;2:28.
7. Gale RP, Horowitz MM, Ash RC, Champlin RE, Goldman JM, Rimm AA, Ringdén O, Stone JAV, Bortin MM. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994;120: 646.
8. Fefer A, Cheever MA, Greeberg PD. Identical-twin (Syngeneic) marrow transplantation for hematologic cancers. J Natl Cancer Inst 1986;76:1269.
9. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RA, Herzig RH, Hong R, Masaoka T, Rimm AA. Ringdén O, Speck B, Weiner RS, Bortin MM. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991;78:2120.
10. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D. Van Rhee F, Mittermueller J, de Witte T, Holler E, Ansari H. Graft-vs-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041.
11. Cullis JO, Jiang YZ, Schwarer AP, Hughes TP, Barrett AJ, Goldman JM. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 1992;79:1379.
12. Antin JH. Graft-versus-leukemia: No longer an epiphenomenon. Blood 1993;82:2273,
13. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, Van Tuinen P, Horowitz MM, Flomenberg N. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993;82:2310.
14. Apperley JF, Jones L, Hale G, Waldmann H, Hows J, Rombos Y, Tsatalas C, Marcus RE, Goolden AWG, Gordon-Smith EC, Catovsky D, Galton DAG, Goldman JM. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1986;1:53.
15. Goldman JM, Gale RP, Bortin MM, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Horowitz MM, Marmont AM, McGlave PB, Messner HA, Rimm AA, Rozman C, Speck B, Tura S, Weiner RS. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann Intern Med 1988;108:806.
16. Mackinnon S, Barnett L, Heller G, O'Reilly RJ. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood 1994;83:3409.
17. Papadopoulos EB, Carabasi MH, Castro-Malaspina H, Childs BH, Mackinnon S, Boulad F, Gillio AP, Kernan NA, Small TN, Szabolcs P, Taylor J, Yahalom J, Collins NH, Bleau SA, Black PM, Heller G, O'Reilly RJ, Young JW. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: Freedom from relapse in the absence of graft-versus-host disease. Blood 1998;91:1083.
18. Collins RH, Jr., Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15: 433.
19. Raanani P, Dazzi F, Sohal J, Szydlo RM, Van Rhee F, Reiter A, Lin F, Goldman JM, Cross NCP. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol 1997;99:945.
20. Bacigalupo A, Soracco M, Vassallo F, Abate M, Van Lint MT, Gualandi F, Lamparelli T, Occhini D, Mordini N, Bregante S, Figari O, Benvenuto F, Sessarego M, Fugazza G, Carlier P, Valbonesi M. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant 1997;19:927.
21. Rondón G, Giralt S, Huh Y, Khouri I, Andersson B, Andreeff M, Champlin R. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1996;18:669.
22. Van Besien KW, De Lima M, Giralt SA, Moore DF, Jr., Khouri IF, Rondón G, Mehra R, Andersson BS, Dyer C, Cleary K, Przepiorka D, Gajewski JL, Champlin RE. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997; 19:977.
23. Khouri I, Keating MJ, Przepiorka D, O'Brien S, Giralt S, Korbling M, Champlin R. Engraftment and induction of GVL with fludarabine-based non-ablative preparative regimen in patients with chronic lymphocytic leukemia. Blood 1996;88:301a.
24. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LLM, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997;90:4206.
25. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87:1196.
26. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ. Graft-versus-myeloma effect in two cases. Lancet 1996; 347:800.
27. Ueno NT, Rondón G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Körbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, Van Besien K, Hortobagyi GN, Champlin RE. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998;16:986.
28. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gächter A, Knapp R, Böck G, Gassner C, Schiller L, Petersen F, Niederwieser D. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996;88:1501.
29. Korngold R, Sprent J. T cell subsets and graft-versus-host disease. Transplantation 1987;44:335.
30. Korngold R, Sprent J. Variable capacity of L3 T4 + T cells to cause lethal graft versus host disease across minor histocompatibility barriers in mice. J Exp Med 1987;165:52.
31. Ferrara JLM, Deeg HJ. Mechanisms of disease: Graft-versus-host disease. N Engl J Med 1991;324:667.
32. - phenotype are effectors of experimental cutaneous graft-versus-host disease. Proc Natl Acad Sci USA 1991;88:10890.
33. Ferrara JLM, Guillen FJ, vanDijken PJ, Marion A, Murphy GF, Burakoff SJ. Evidence that large granular lymphocytes of donor origin mediate acute graft-versus-host disease. Transplant 1989; 47:50.
34. Ferrara JLM, Abhyankar S, Gilliland DG. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant. Proc 1993;25:1216.
35. Faber LM, Van Luxemburg-Heijs SAP, Willemze R, Falkenburg JHF. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 1992;176:1283.
36. Faber LM, Van der Hoeven J, Goulmy E, Hooftman-den Otter AL, Van Luxemburg-Heijs SAP, Willemze R, Falkenburg JHF. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Clin Invest 1995;96:877.
37. Van der Harst D, Goulmy E, Falkenburg JHF, Kooij-Winkelaar YMC, Van Luxemburg-Heijs SAP, Goselink HM, Brand A. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 1994; 83:1060.
38. Truitt RL, Atasoylu AA. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 1991;8:51.
39. Okunewick JP, Kociban DL, Machen LL, Buffo MJ. The role of CD4 and CD8 T cells in the graft-versus-leukemia response in Rauscher murine leukemia. Bone Marrow Transplant 1991;8:445.
40. Okunewick JP, Kociban DL, Machen LL, Buffo MJ. Evidence for a possible role of Asialo-GM1-positive cells in the graft-versus-leukemia repression of a murine type-C retroviral leukemia. Bone Marrow Transplant 1995;16:451.
41. Jiang Y-Z, Barrett AJ. Cellular and cytokine mediated effects of CD4-positive lymphocyte lines generated in vitro against chronic myelogeneous leukemia. Exp Hematol 1995;23:1167.
42. + T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. Br J Haematol 1996;93:606.
43. Sosman JA, Oettel KR, Smith SD, Hank JA, Fisch P, Sondel PM. Specific recognition of human leukemic cells by allogeneic T cells. II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells. Blood 1990;75:2005.
44. Jiang YZ, Barrett AJ, Goldman JM, Mavroudis DA. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol 1997; 74:1.
45. Zeis M, Uharek L, Glass B, Gaska T, Steinmann J, Gassmann W, Löffler H, Müller-Ruchholtz W. Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice. Transplantation 1995;59:1734.
46. Glass B, Uharek L, Zeis M, Loeffler H, Mueller-Ruchholtz W, Gassmann W. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia. Br J Haematol 1996;93:412.
47. Hauch M, Gazzola MV, Small T, Bordignon C, Barnett L, Cunningham I, Castro-Malaspinia H, O'Reilly RJ, Keever CA. Antileukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 1990;75:2250.
48. Giralt SA, Champlin RE. Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood 1994;84:3603.
49. Keil F, Haas OA, Fritsch G, Kalhs P, Lechner K, Mannhalter C, Reiter E, Niederwieser D, Hoecker P, Greinix HT. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood 1997;89:3113.
50. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs B, Gillio A, Kernan NA, Small T, Young J, O'Reilly RJ. Adoptive immunotherapy evaluating escalating doses of donor leukeocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separataiton of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995;86:1261.
51. Rahman SL, Mahendra P, Nacheva E, Sinclair P, Arno J, Marcus RE. Achievement of complete cytogenetic remission after two very low-dose donor leucocyte infusions in a patient with extensive cGVHD relapsing in accelerated phase post allogeneic BMT for CML. Bone Marrow Transplant 1998;21:955.
52. + T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 1990;76:418.
53. Champlin RE, Jansen J, Ho W, Gajewski J, Nimer S, Lee K, Territo M, Winston D, Tricot G, Reichert T. Retention of graft-versus-leukemia using selective depletion of CD8 positive T lymphocytes for prevention of graft versus host disease following bone marrow transplantation for chronic myelogenous leukemia. Transplantation Proc 1991;23:1695.
54. + cells for prevention of graft-versus-host disease after bone marrow transplantation: a randomized controlled trial. Transplantation 1994;57:82.
55. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Guo J, Lee M, Gajewski J, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin R. CD8+ depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: graft vs leukemia without graft vs. host disease. Blood 1995;86:4337.
56. + donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998;91:3671.
57. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997;276:1719.
58. Munshi NC, Govindarajan R, Drake R, Ding LM, Iyer R, Saylors R, Kornbluth J, Marcus S, Chiang Y, Ennist D, Kwak L, Reynolds C, Tricot G, Barlogie B. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood 1997;89: 1334.
59. Tiberghien P, Reynolds CW, Keller J, Spence S, Deschaseaux M, Certoux J-M, Contassot E, Murphy WJ, Lyons R, Chiang Y, Hervé P, Longo DL, Ruscetti FW. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation. Blood 1994;84:1333.
60. Giralt S, Estey E, Albitar M, Van Besien K, Rondon G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Körbling M, Keating M, Kantarjian H, Champlin R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531.
61. Khouri I, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S, Von Wolff B, Giralt S, Gajewski JG, Mehra R, Ippoliti C, Claxton D, Champlin RE. Transplant Lite: induction of graft-versus-leukemia using fludarabine-based nonablative chemotherpy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817.
62. Giralt S, Cohen A, Mehra R, Gajewski J, Andersson B, Przepiorka D, Khouri I, Korbling M, Davis M, Van Besien K, Ippoliti C, Bruton J, Anderlini P, Ueno N, Champlin R. Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenitor cell transplantation in poor candidates for conventional myeloablative conditioning. Blood 1997; 90:1853a.
63. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, OR R. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756.
64. Kelemen E, Masszi T, Reményi P, Barta A, Pálóczi K. Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new, non-myeloablative drug combination. Bone Marrow Transplant 1998;21:747.
65. Bacigalupo A, Van Lint MT, Occhini D, Gualandi F, Lamparelli T, Sogno G, Tedone E, Frassoni F, Tong J, Marmont AM. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991;77:1423.